CO7020877A2 - Anticuerpos anti-asic1 y usos de los mismos - Google Patents

Anticuerpos anti-asic1 y usos de los mismos

Info

Publication number
CO7020877A2
CO7020877A2 CO14162499A CO14162499A CO7020877A2 CO 7020877 A2 CO7020877 A2 CO 7020877A2 CO 14162499 A CO14162499 A CO 14162499A CO 14162499 A CO14162499 A CO 14162499A CO 7020877 A2 CO7020877 A2 CO 7020877A2
Authority
CO
Colombia
Prior art keywords
asic1 antibodies
asic1
antibodies
see annexes
annexes
Prior art date
Application number
CO14162499A
Other languages
English (en)
Inventor
Lynn Macdonald
Min Gao
Marc R Morra
Nicole M Andri-Haber
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7020877(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO7020877A2 publication Critical patent/CO7020877A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Abstract

VER ANEXOS
CO14162499A 2012-01-31 2014-07-25 Anticuerpos anti-asic1 y usos de los mismos CO7020877A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
CO7020877A2 true CO7020877A2 (es) 2014-08-11

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14162499A CO7020877A2 (es) 2012-01-31 2014-07-25 Anticuerpos anti-asic1 y usos de los mismos

Country Status (33)

Country Link
US (3) US9150648B2 (es)
EP (2) EP3453723B1 (es)
JP (1) JP6302844B2 (es)
KR (1) KR102111941B1 (es)
CN (1) CN104093738B (es)
AR (1) AR089852A1 (es)
AU (1) AU2013215254B2 (es)
CA (1) CA2862332C (es)
CL (1) CL2014002019A1 (es)
CO (1) CO7020877A2 (es)
CY (2) CY1121368T1 (es)
DK (2) DK2809681T3 (es)
EA (1) EA028647B1 (es)
ES (2) ES2707599T3 (es)
HK (1) HK1199269A1 (es)
HR (2) HRP20211541T1 (es)
HU (2) HUE042531T2 (es)
IL (2) IL233410A0 (es)
IN (1) IN2014CN04645A (es)
JO (1) JO3547B1 (es)
LT (2) LT2809681T (es)
MX (1) MX358518B (es)
MY (1) MY168748A (es)
NZ (1) NZ626242A (es)
PH (1) PH12014501613A1 (es)
PL (2) PL2809681T3 (es)
PT (2) PT3453723T (es)
RS (2) RS58439B1 (es)
SG (1) SG11201403222UA (es)
SI (2) SI2809681T1 (es)
TW (1) TWI591073B (es)
UY (1) UY34603A (es)
WO (1) WO2013116296A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2809681T1 (sl) 2012-01-31 2019-04-30 Regeneron Pharmaceuticals, Inc. Protitelesa anti-asic1 in njihova uporaba
US10272154B2 (en) 2014-04-15 2019-04-30 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
EP3693386A1 (en) 2014-05-16 2020-08-12 Ablynx NV Immunoglobulin variable domains
CN109053885A (zh) 2014-05-16 2018-12-21 埃博灵克斯股份有限公司 改进的免疫球蛋白可变结构域
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
AU2019211406A1 (en) * 2018-01-26 2020-08-13 Regeneron Pharmaceuticals, Inc. Anti-TMPRSS2 antibodies and antigen-binding fragments
EP3980456A4 (en) * 2019-06-04 2023-01-18 Shanghaitech University AFFINITY MATURED ANTI-ASIC1A ANTIBODIES
KR20220034167A (ko) * 2019-07-11 2022-03-17 메모리얼 슬로안 케터링 캔서 센터 Dll3-표적화 항체 및 이의 용도
JP2022547781A (ja) * 2019-07-23 2022-11-16 シャンハイテック ユニバーシティ Ａｓｉｃ１チャネルアンタゴニスト抗体
AU2020346886A1 (en) * 2019-09-13 2022-04-14 Memorial Hospital For Cancer And Allied Diseases Anti-CD371 antibodies and uses thereof
IL310700A (en) * 2021-08-09 2024-04-01 Merck Patent Gmbh Proteins that uncouple cell-mediated tumor cytotoxicity from proinflammatory cytokine release
CA3230628A1 (en) * 2021-09-02 2023-03-09 John T. POIRIER Anti-dll3 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
AU9732498A (en) 1997-10-29 1999-05-17 Mcgill University Dna encoding a human proton-gated ion channel and uses thereof
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
EP1527100B1 (en) * 2002-03-29 2009-07-01 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US20070092444A1 (en) * 2003-09-11 2007-04-26 The Uab Research Foundation Inhibition of inward sodium currents in cancer
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
US20070004680A1 (en) 2004-03-30 2007-01-04 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
PT1838733E (pt) * 2004-12-21 2011-12-13 Medimmune Ltd Anticorpos direccionados a angiopoietina-2 e respectivos usos
BRPI0608096A2 (pt) * 2005-04-26 2009-11-10 Pfizer anticorpos p-caderina
WO2007143168A2 (en) 2006-06-02 2007-12-13 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
JP5382692B2 (ja) * 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
EP2043650A2 (en) * 2006-07-14 2009-04-08 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
ATE483985T1 (de) 2007-04-03 2010-10-15 Ilegusavnid Genetics Resource Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2288922B1 (en) * 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
EP2356146A1 (en) * 2008-11-07 2011-08-17 Fabrus Llc Anti-dll4 antibodies and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
SI2809681T1 (sl) 2012-01-31 2019-04-30 Regeneron Pharmaceuticals, Inc. Protitelesa anti-asic1 in njihova uporaba
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Also Published As

Publication number Publication date
HRP20211541T1 (hr) 2021-12-24
PL2809681T3 (pl) 2019-05-31
SI3453723T1 (sl) 2021-11-30
LT2809681T (lt) 2019-02-11
RS62454B1 (sr) 2021-11-30
HUE056335T2 (hu) 2022-02-28
MX358518B (es) 2018-08-24
IL233410A0 (en) 2014-08-31
US20180222976A1 (en) 2018-08-09
US10513557B2 (en) 2019-12-24
AR089852A1 (es) 2014-09-24
ES2886123T3 (es) 2021-12-16
EP3453723A3 (en) 2019-04-10
IL254416B (en) 2018-03-29
IN2014CN04645A (es) 2015-09-18
PH12014501613B1 (en) 2014-10-13
ES2707599T3 (es) 2019-04-04
US9150648B2 (en) 2015-10-06
CA2862332C (en) 2021-05-18
HK1199269A1 (en) 2015-06-26
CA2862332A1 (en) 2013-08-08
CY1121368T1 (el) 2020-05-29
CY1124778T1 (el) 2022-11-25
JO3547B1 (ar) 2020-07-05
LT3453723T (lt) 2021-09-10
HUE042531T2 (hu) 2019-07-29
AU2013215254B2 (en) 2017-08-31
MY168748A (en) 2018-11-30
EA201491452A1 (ru) 2014-11-28
NZ626242A (en) 2017-02-24
HRP20190358T1 (hr) 2019-04-05
DK3453723T3 (da) 2021-09-13
BR112014018651A2 (pt) 2017-07-04
SI2809681T1 (sl) 2019-04-30
EP2809681B1 (en) 2018-12-05
KR102111941B1 (ko) 2020-05-18
DK2809681T3 (en) 2019-03-11
US20130195878A1 (en) 2013-08-01
KR20140125363A (ko) 2014-10-28
US20160002332A1 (en) 2016-01-07
JP2015508063A (ja) 2015-03-16
SG11201403222UA (en) 2014-07-30
AU2013215254A1 (en) 2014-07-03
IL254416A0 (en) 2017-11-30
EP3453723A2 (en) 2019-03-13
PL3453723T3 (pl) 2022-01-03
PH12014501613A1 (en) 2014-10-13
CN104093738A (zh) 2014-10-08
PT2809681T (pt) 2019-02-18
PT3453723T (pt) 2021-09-07
RS58439B1 (sr) 2019-04-30
EP2809681A1 (en) 2014-12-10
UY34603A (es) 2013-07-31
JP6302844B2 (ja) 2018-03-28
CL2014002019A1 (es) 2015-01-16
TWI591073B (zh) 2017-07-11
MX2014008541A (es) 2014-10-24
EA028647B1 (ru) 2017-12-29
TW201335182A (zh) 2013-09-01
WO2013116296A1 (en) 2013-08-08
CN104093738B (zh) 2018-05-18
EP3453723B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
CO7121320A2 (es) Anticuerpos anti-hla-b*27 y usos de estos
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CO7061078A2 (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos
CO7020859A2 (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
CO7170179A2 (es) Moduladores del receptor de estrogeno y sus usos
CO7101248A2 (es) Compuesos de tetrazolinona y su uso como pesticidas
BR112015006198A2 (pt) conjunto de cadeira
BR112015008272A2 (pt) cápsula para preparação de bebidas
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CO7030961A2 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CO7091177A2 (es) Inhibidores de la beta-secretasa
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
CO6870031A2 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
CO6862154A2 (es) Metabolitos de trans-clomifeno y usos de los mismos
BR112015007217A2 (pt) compostos e usos do composto